
    
      This trial is a 28-day, single-arm open-label phase III trial to evaluate safety of the house
      dust mite SLIT-tablet in adolescents (12-17 years of age) with HDM allergic
      rhinitis/rhinoconjunctivitis with or without asthma. Approximately 250 adolescents will be
      enrolled in the trial and will receive the house dust mite SLIT tablet. The trial is
      conducted in several European countries.
    
  